Methods to analyze real-world databases and registries

Bulletin of the NYU Hospital for Joint Diseases

Volumn 67, Issue 2, 2009, Pages 193-197

  Kremers, Hilal Maradit ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ACCURACY; ANALYTIC METHOD; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONFERENCE PAPER; DATA ANALYSIS; DATA BASE; DISEASE COURSE; DISEASE REGISTRY; DRUG EXPOSURE; ECOLOGY; HEALTH HAZARD; HEART INFARCTION; HISTORY; HUMAN; INFORMATION PROCESSING; MEDICAL INFORMATION SYSTEM; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PREDICTION; REGISTER; RHEUMATIC DISEASE; RHEUMATOLOGY; RISK ASSESSMENT; RISK FACTOR; STATISTICS; TIME SERIES ANALYSIS;

DATABASES AS TOPIC; EVIDENCE-BASED MEDICINE; GUIDELINES AS TOPIC; HUMANS; OBSERVATION; REGISTRIES; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; RHEUMATIC DISEASES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67649515088     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Gladman DD, Rahman P, Krueger GG, et al. Clinical and genetic registries in psoriatic disease. J Rheumatol. 2008 Jul;35(7):1458-1463 (Pubitemid 352000804)
2. Zink A, Askling J, Dixon WG, et al. European Biologics Registers - Methodology, selected results, and perspectives. Ann Rheum Dis. 2008 Jul 22; Epub ahead of print.
3. Kremer JM, Gibofsky A, Greenberg JD. The role of drug and disease registries in rheumatic disease epidemiology. Curr Opin Rheumatol. 2008 Mar;20(2):123-130
4. Lu LJ, Wallace DJ, Navarra SV, Weisman MH. Lupus registries: evolution and challenges. Semin Arthritis Rheum. 2008 Nov 6; Epub ahead of print.
5. Wolfe F. A short history of data banking in the United States from 1974 to 2003. J Rheumatol Suppl. 2004 Mar;69:41-45
6. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005 Feb 5-11;365(9458):475-481
7. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005 Apr;58(4):323-337 (Pubitemid 40601980)
8. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. Jun 2007;56(6):1754-1764
9. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med. Jun 22 2000;342(25):1907-1909
10. Gliklich RE, Dreyer NA (eds): Registries for Evaluating Patient Outcomes: A User's Guide. (Prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under Contract No. HHSA29020050035I TO1.) AHRQ Publication No. 07-EHC001-1. Rockville, MD: Agency for Healthcare Research and Quality, April 2007.
11. Sheng PY, Konttinen L, Lehto M, et al. Revision total knee arthroplasty: 1990 through 2002. A review of the Finnish arthroplasty registry. J Bone Joint Surg Am. 2006 Jul;88(7):1425-1430
12. Lamont EB, Dias LE. Secular changes in NSAID use and invasive colorectal cancer incidence: an ecological study. Cancer J. 2008 Jul-Aug;14(4):276-277
13. Brownstein JS, Sordo M, Kohane IS, Mandl KD. The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarction. PLoS ONE. 2007;2(9):e840.
14. van Vollenhoven RF, Askling J. Rheumatoid arthritis registries in Sweden. Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S195-200.
15. Maradit Kremers H, Crowson CS, Gabriel SE. Rochester Epidemiology Project: a unique resource for research in the rheumatic diseases. Rheum Dis Clin North Am. 2004;30:819-34.
16. Ward MM. Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs? Arthritis Rheum. 2001;44(6):1467-1469
17. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol. 2008 Sep-Oct;26(5 Suppl 5):S35-61.
18. Doran MF, Pond GR, Crowson CS, et al. Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum. 2002;46(3):625-631 (Pubitemid 34214244)
19. Salvarani C, Crowson CS, O'Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum. 2004;51(2):264-268 (Pubitemid 38468712)
20. Doran M, Crowson C, Pond G, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum. 2002;46(9):2287-93.
21. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum. 2005 Feb 3;52(2):402-411
22. Kremer JM. The CORRONA database. Autoimmun Rev. 2006 Jan;5(1):46-54.
23. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: A population-based study. Arthritis Rheum. 2005 Mar;52(3):722-732
24. Maradit-Kremers HM, Nicola P, Crowson CS, et al. Therapeutic strategies in rheumatoid arthritis over a 40-year period. J Rheumatol. 2004 Dec;31(12):2366-2373 (Pubitemid 39603083)
25. Walker AM. Confounding by indication. Epidemiology. 1996;7(4):335-336
26. Wolfe F, Flowers N, Burke TA, et al. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol. 2002;29(5):1015-1022 (Pubitemid 34493508)
27. Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359(9313):1173-1177 (Pubitemid 34304256)
28. Wiles NJ, Lunt M, Barrett EM, et al. Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. Arthritis Rheum. 2001;44(5):1033-1042 (Pubitemid 32433607)
29. Ting G, Schneeweiss S, Scranton R, et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther. 2008;10(4):R95; 2008 Aug 21; Epub ahead of print.
30. Bukhari MA, Wiles NJ, Lunt M, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum. 2003;48(1):46-53. (Pubitemid 36091646)
31. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003 Nov 1;158(9):915-920 (Pubitemid 37323253)
32. Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther. 2007 Aug;82(2):143-156
33. Doran MF, Crowson CS, O'Fallon WM, Gabriel SE. The effect of oral contraceptives and estrogen replacement therapy on the risk of rheumatoid arthritis: a population based study. J Rheumatol. 2004;31(2):207-213 (Pubitemid 38160739)
34. Kallberg H, Jacobsen S, Bengtsson C, et al. Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-control studies. Ann Rheum Dis. 2009 Feb;68(2):222-227
35. de Craen AJ, Gussekloo J, Vrijsen B, Westendorp RG. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol. 2005 Jan 15;161(2):114-120 (Pubitemid 40096787)